Coya Therapeutics (NASDAQ:COYA) Given “Buy” Rating at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Coya Therapeutics (NASDAQ:COYA) in a report issued on Tuesday morning,Benzinga reports. The firm currently has a $18.00 price objective on the stock.

Separately, Chardan Capital reissued a “buy” rating and issued a $14.00 price objective on shares of Coya Therapeutics in a report on Thursday, March 20th.

Coya Therapeutics Price Performance

Shares of NASDAQ COYA opened at $6.64 on Tuesday. The firm has a market capitalization of $111.05 million, a PE ratio of -10.22 and a beta of 0.49. Coya Therapeutics has a 1-year low of $4.65 and a 1-year high of $10.24. The business’s fifty day moving average price is $6.19 and its two-hundred day moving average price is $6.42.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings data on Tuesday, March 18th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.14. The firm had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.10 million. Equities research analysts expect that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC boosted its stake in Coya Therapeutics by 3.3% during the 3rd quarter. Geode Capital Management LLC now owns 142,309 shares of the company’s stock valued at $918,000 after purchasing an additional 4,485 shares in the last quarter. Newbridge Financial Services Group Inc. acquired a new stake in shares of Coya Therapeutics in the fourth quarter valued at $401,000. AIGH Capital Management LLC boosted its stake in Coya Therapeutics by 85.0% during the fourth quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company’s stock valued at $6,883,000 after buying an additional 551,725 shares in the last quarter. CM Management LLC grew its holdings in Coya Therapeutics by 11.1% during the fourth quarter. CM Management LLC now owns 160,000 shares of the company’s stock worth $917,000 after acquiring an additional 15,941 shares during the period. Finally, Jane Street Group LLC bought a new stake in Coya Therapeutics in the fourth quarter worth about $74,000. Institutional investors and hedge funds own 39.75% of the company’s stock.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.